TY - JOUR
T1 - The Contribution of Chemoattractant GPCRs, Formylpeptide Receptors, to Inflammation and Cancer
AU - Liang, Weiwei
AU - Chen, Keqiang
AU - Gong, Wanghua
AU - Yoshimura, Teizo
AU - Le, Yingying
AU - Wang, Ying
AU - Wang, Ji Ming
N1 - Funding Information:
The authors thank Ms. Cheri Rhoderick for secretarial assistance. Funding. This project has been supported in part by Federal funds from the National Cancer Institute (NCI), National Institutes of Health (NIH), under Contract No. HSN261200800001E, and by the Intramural Research Programs of the NCI. This project has been also supported in part by China Scholarship Council Grant (201706010305 to WL) and the National Natural Science Foundation of China (31470842 and 31770940 to YW) and the Natural Science Foundation of Beijing Municipality (7192097 to YW).
Publisher Copyright:
© Copyright © 2020 Liang, Chen, Gong, Yoshimura, Le, Wang and Wang.
PY - 2020/1/24
Y1 - 2020/1/24
N2 - A hallmark of inflammatory responses is leukocyte mobilization, which is mediated by pathogen and host released chemotactic factors that activate Gi-protein-coupled seven-transmembrane receptors (GPCRs) on host cell surface. Formylpeptide receptors (FPRs, Fprs in mice) are members of the chemoattractant GPCR family, shown to be critical in myeloid cell trafficking during infection, inflammation, immune responses, and cancer progression. Accumulating evidence demonstrates that both human FPRs and murine Fprs are involved in a number of patho-physiological processes because of their expression on a wide variety of cell types in addition to myeloid cells. The unique capacity of FPRs (Fprs) to interact with numerous structurally unrelated chemotactic ligands enables these receptors to participate in orchestrated disease initiation, progression, and resolution. One murine Fpr member, Fpr2, and its endogenous agonist peptide, Cathelicidin-related antimicrobial peptide (CRAMP), have been demonstrated as key mediators of colon mucosal homeostasis and protection from inflammation and associated tumorigenesis. Recent availability of genetically engineered mouse models greatly expanded the understanding of the role of FPRs (Fprs) in pathophysiology that places these molecules in the list of potential targets for therapeutic intervention of diseases.
AB - A hallmark of inflammatory responses is leukocyte mobilization, which is mediated by pathogen and host released chemotactic factors that activate Gi-protein-coupled seven-transmembrane receptors (GPCRs) on host cell surface. Formylpeptide receptors (FPRs, Fprs in mice) are members of the chemoattractant GPCR family, shown to be critical in myeloid cell trafficking during infection, inflammation, immune responses, and cancer progression. Accumulating evidence demonstrates that both human FPRs and murine Fprs are involved in a number of patho-physiological processes because of their expression on a wide variety of cell types in addition to myeloid cells. The unique capacity of FPRs (Fprs) to interact with numerous structurally unrelated chemotactic ligands enables these receptors to participate in orchestrated disease initiation, progression, and resolution. One murine Fpr member, Fpr2, and its endogenous agonist peptide, Cathelicidin-related antimicrobial peptide (CRAMP), have been demonstrated as key mediators of colon mucosal homeostasis and protection from inflammation and associated tumorigenesis. Recent availability of genetically engineered mouse models greatly expanded the understanding of the role of FPRs (Fprs) in pathophysiology that places these molecules in the list of potential targets for therapeutic intervention of diseases.
KW - FPRs
KW - cancer
KW - chemotaxis
KW - immunity
KW - infection
KW - inflammation
KW - regulation
UR - http://www.scopus.com/inward/record.url?scp=85079165456&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85079165456&partnerID=8YFLogxK
U2 - 10.3389/fendo.2020.00017
DO - 10.3389/fendo.2020.00017
M3 - Review article
AN - SCOPUS:85079165456
SN - 1664-2392
VL - 11
JO - Frontiers in Endocrinology
JF - Frontiers in Endocrinology
M1 - 17
ER -